The antisera were tested at two different dilutions, 1:8 and 1:16. Fig. 5 shows the number of CFUs recovered after incubation of pneumococci with peritoneal cells in the presence of sera at the dilution of 1:16 with the exception for Strain P 1079 in which the anti-PspA 94/01 opsonophagocitic http://www.selleckchem.com/products/Bortezomib.html activity was observed only at a dilution of 1:8. The anti-PspA 245/00 antisera (clade 1) was able to reduce the number of CFUs recovered in at least 40% for strains bearing PspA clade 1 and 30% for strains containing clade 2 PspA, reaching a maximum of 50% in strains of the same clade. Furthermore, sera from

mice immunized with PspA 94/01 (clade 2), was able to mediate killing of at least 30% of the bacteria expressing PspAs clade Pomalidomide mouse 1 or 2. The only exception was that of strain P278, for which the reduction in CFU recovered was only 17%. The maximum reduction induced by anti-PspA 94/01 antisera was 46 and 63% for strains bearing PspA 1 and 2, respectively. The CFU reduction mediated by anti-PspA 245/00 and 94/01 was statistically significant when compared to serum from mice receiving Aluminum hydroxide (except

for strain P 278). Both sera induced similar degrees of bacterial phagocytosis among pneumococci bearing family 1 PspAs, since there were no statistically significant differences between the effect induced by anti-PspA 245/00 and anti-PspA 94/01 antisera. Microscopical analysis of the samples revealed the interaction between the phagocytes and the pneumococci incubated with both sera (Fig. 6). In the control group, after incubation of the cells with bacteria previously treated with non-specific

antibodies, no interaction was observed, as depicted by the mononuclear cell in Fig. 6A. On the other hand, incubation of the cells with a PspA clade 1 expressing strain, previously opsonized with anti-PspA 94/01 (clade 2), induced a strong interaction between the bacteria and the peritoneal cells, as demonstrated by the pneumococci-covered macrophage in Fig. 6 B. Noteworthy is the ability of the anti-PspA 94/01 antibodies to mediate phagocytosis of a pneumococcal strain expressing a heterologous PspA, a strong indication of cross-protection. A similar TCL result was obtained when cells were cultured in the presence of the pneumococcal strain P 69, containing PspA clade 1, previously incubated with anti-PspA245/00, also clade 1; Fig. 6C and D shows a large number of internalized bacteria in a macrophage and a neutrophil, respectively. PspA is a promising vaccine candidate against pneumococcal disease; however, it is structural and serological variability could limit the coverage of a PspA-based vaccine. Therefore, understanding the nature of PspA’s variability has been the focus of many studies regarding anti-pneumococcal vaccine development. Hollingshead et al. [12], grouped most PspAs into two major families, 1 and 2, which were subdivided into 5 clades.